Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management
| Autor: | Walter-Michael Halbmayer, Franz X. Roithinger, Ansgar Weltermann, Paul A. Kyrle, F. Längle, M. Gottsauner-Wolf, Robert Zweiker, Reinhard Windhager, J. M. Hiesmayr, Hans Domanovits, Bernd Eber, C. Wolf, Herbert H. Watzke, Marianne Brodmann |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
medicine.medical_specialty Premedication Consensus Report Postoperative Hemorrhage Bridging Perioperative Care Dabigatran Atrial Fibrillation medicine Humans In patient Chirurgie Intensive care medicine Medicine(all) medicine.diagnostic_test business.industry Bleeding Endoscopy Atrial fibrillation General Medicine Perioperative medicine.disease Surgery Austria Hemostasis Sufficient time Practice Guidelines as Topic beta-Alanine Benzimidazoles Female Blutung business Endoskopie medicine.drug |
| Zdroj: | Wiener Klinische Wochenschrift |
| ISSN: | 1613-7671 0043-5325 |
| Popis: | Summary In any type of invasive surgery, the patient’s individual risk of thromboembolism has to be weighed against the risk of bleeding. Based on various everyday situations in clinical routine, the purpose of the present expert recommendations is to provide appropriate perioperative and periinterventional management for patients with atrial fibrillation undergoing long-term treatment with the thrombin inhibitor dabigatran. As we currently have no routine laboratory test to measure therapeutic levels of the substance or the risk of bleeding, general measures such as a standardized documentation of the patient’s history, a sufficient time interval between the last preoperative dose and the procedure, and careful control of local hemostasis should be given special attention. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink